Press release
Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones
Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Expected in Early January 2023 FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq:
About this update from Geron Corporation
[{"type":"text","content":"\nTop-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Expected in Early January 2023\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2021. The Company ended 2021 with $212.7 million in cash and marketable securities, which the Company believes is sufficient to fund current operations through the end of the first quarter of 2023.\n\n“We made significant accomplishments in 2021 to advance the development of imetelstat toward two important Phase 3 data readouts, which if positive, have the potential to transform patient care in lower risk MDS and refractory MF,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “With completion of enrollment in IMerge Phase 3 last October, we look forward to top-line results from that trial in early January 2023. If those results confirm similar safety, as well as the depth, breadth and durability of transfusion independence that was observed in our Phase 2 trial, then upon approval of an NDA, we expect our U.S. commercial launch of imetelstat in lower risk MDS to occur as early as the first half of 2024.”\n\nDr. Scarlett added, “In 2021, we also made progress with the IMpactMF Phase 3 trial in refractory MF, by opening 50% of the planned clinical sites to patient enrollment. In 2022, we plan to open the rest of the selected clinical sites to enable the planned interim analysis in 2024.”\n\nDr. Scarlett also noted, “Building on the strong evidence of imetelstat’s disease modification potential from our Phase 2 trials, we started several new programs in 2021. We believe that the data to be generated from these programs over the next few years will provide strategic value to the imetelstat franchise through the potential expansion into new myeloid and lymphoid hematologic indications, as well as into combination regimens.”\n\nKey Upcoming Milestones Expected\n\n\nTop-line results from IMerge Phase 3 in early January 2023\n\n\nOpen the rest of the selected clinical sites in IMpactMF for enrollment to enable the planned interim analysis in 2024\n\n\nExpand into additional indicatio...